Previous clinical reports which have examined the relationship between ER content and responsiveness to chemotherapy in advanced or disseminated breast cancer are less than satisfactory. There is a multitude of critical flaws in the reviews, which are retrospective, nonrandomized, and without standardization. The correlation of ER and the biology of breast cancer, as observed in clinical reports and in the laboratory, and studies examining tumor characteristics which influence its responsiveness to chemotherapy support the hypothesis that the presence of ER should be associated with tumors which are more well-differentiated, slower growing, and less responsive to chemotherapy. Perhaps a prospective, randomized trial is necessary to conclusively determine the relationship between ER and chemotherapy. The findings correlating ER negativity and increased responsiveness to doxorubicin are of potential clinical significance, and suggested a clinical trial to further study this association.
|Original language||English (US)|
|Number of pages||4|
|Journal||Cancer Treatment Reports|
|State||Published - Jan 1 1984|
ASJC Scopus subject areas
- Cancer Research